Latest Novartis Group Stories

- Afinitor significantly reduced tumor size by 50% or more in one out of three patients with refractory or relapsed lymphoma - Phase III study underway to explore potential of Afinitor to prevent relapse in patients with the most common type of non-Hodgkin's lymphoma EAST HANOVER, N.J., June 8 /PRNewswire/ -- New data show that Afinitor(R) (everolimus) tablets significantly shrunk tumors in 33% of patients with relapsed non-Hodgkin's lymphoma (NHL) and Hodgkin's disease(1). Based on...

- Oral presentation on Sandostatin(R) LAR Depot Phase III data shows significant antitumor benefit in patients with advanced neuroendocrine tumors of the midgut - Early data show that at eight weeks of treatment, Afinitor(R) stabilized or reduced tumor size in 61% of patients with advanced liver cancer - New data reveal postmenopausal women with breast cancer taking Femara(R) experience better cognitive function than those taking tamoxifen - Phase II data show potential of...

- This approval will provide greater convenience and broader access to an effective treatment option to the 50 million Americans(1) suffering from frequent heartburn - Once-daily, prescription-strength Prevacid(R) 24HR is the first OTC proton pump inhibitor approved for the treatment of frequent heartburn in the US since 2003 - Prescription-strength Prevacid 24HR treats frequent heartburn for a full 24 hours BASEL, Switzerland, May 14 /PRNewswire/ -- Novartis announced today that...

- Afinitor more than doubled time without tumor growth and reduced the risk of disease progression or death by 67% compared with placebo - Only once-daily oral cancer treatment to directly target mTOR, a protein inside the cell that controls tumor cell division and blood vessel growth - Phase III trials underway to explore potential of Afinitor in multiple additional cancers EAST HANOVER, N.J., March 30 /PRNewswire/ -- Novartis announced today that Afinitor(R) (everolimus) tablets has...

- After eight weeks of treatment, RAD001 halted tumor growth in 55% of advanced gastric cancer patients previously treated with chemotherapy - Based on these promising data, Novartis will initiate a Phase III trial of RAD001 for advanced gastric cancer patients - Gastric cancer is the second leading cause of cancer death worldwide with the majority of new cases occurring in East Asia EAST HANOVER, N.J., Jan. 13 /PRNewswire/ -- Data released today show RAD001 (also known as everolimus;...

Use of Gleevec after surgery shows significant benefit for gastrointestinal stromal tumor (GIST) patients, dramatically reducing risk of relapse GIST, a life-threatening cancer, recurs in as many as one of two patients; recurrent tumors are often more aggressive than primary tumors For GIST patients who were assigned to Gleevec, more than nine out of 10 remained cancer-free based on a 14-month median follow up EAST HANOVER, N.J., Dec. 19 /PRNewswire/ -- Novartis announced today that...

EAST HANOVER, N.J., Dec. 12 /PRNewswire/ -- New data from two early clinical studies show that RAD001(R) (everolimus) may overcome resistance to Herceptin(R) (trastuzumab)* in women with HER2-positive metastatic breast cancer. These results support the initiation of a Phase III clinical trial program to fully explore the potential of RAD001 (proposed brand name Afinitor(R)) in breast cancer. Two Phase I studies were presented today during the CTRC-AACR San Antonio Breast Cancer...

Adding Zometa to chemotherapy prior to surgery led to an additional 33% reduction in tumor size, resulting in fewer mastectomies New data are first to demonstrate direct effect of Zometa to help shrink primary tumors; further evidence of Zometa as a potential anticancer therapy EAST HANOVER, N.J., Dec. 11 /PRNewswire/ -- New data released today demonstrate that the addition of Zometa(R) (zoledronic acid) injection to standard chemotherapy before breast cancer surgery reduces the size of...

EAST HANOVER, N.J., Oct. 8 /PRNewswire-FirstCall/ -- An early proof-of-concept study presented today shows promising results for imatinib mesylate in the treatment of pulmonary arterial hypertension (PAH), a severe, incurable blood vessel disorder. Preliminary findings from a 59-patient, multi-center Phase II clinical trial suggest imatinib mesylate provides a treatment benefit, as demonstrated by a significant improvement in pulmonary vascular resistance and a numerical increase in cardiac...

EAST HANOVER, N.J., Sept. 16 /PRNewswire-FirstCall/ -- New data continue to demonstrate the potential benefit of RAD001 (everolimus) for patients with advanced kidney cancer who have failed standard therapies. Updated study findings from the RECORD-1 (REnal Cell cancer treatment with Oral RAD001 given Daily) study show that patients receiving RAD001 had no tumor growth for nearly 5 months vs. 1.9 months for patients receiving placebo (hazard ratio = 0.33 with 95% CI 0.25 to 0.43; p-value <...